@DKarikios

Dad/hubby|PhD|Med onc@Nepean|A/Prof at USyd|Interests: GI/lung cancer|value|fin tox|Luv Rabbitohs, Liverpool & Dr Who| @csoncol oncologist. Opinions = mine

 Sydney - Australia
Joined June 2013
  • Tweets3.6K
  • Following1.3K
  • Followers1.9K
240Media
If you are coming to the @MOGA_ORG ASM and have ideas for the CSO Pacific Hub then please join us Details below:
Common Sense Oncology
@csoncolJul 24
CSO Pacific Hub is meeting at the Medical Oncology Group of Australia's Annual Scientific Meeting! Join us on Wednesday, August 5th, at 11 am in Norfolk Hall to discuss ideas. Hear from Dr. Dario Trapani, Medical Oncologist at the European Institute of Oncology in Milan, Italy and Professor of Oncology and Haemato-Oncology at the University of Milan. He currently serves as the Chair of Cancer Medicines Committee at ESMO and is a member of various working groups of Common Sense Oncology. See you there! #CommonSenseOncology #CancerCare #MOGAASM @MOGA_ORG
1
2
291
Dr Deme Karikios retweeted
Common Sense Oncology
@csoncolOct 20
The CSO Symposium at ESMO is happening this Friday, October 23rd! RSVP here: forms.gle/ETTmXfLavnSwh2by5 #CommonSenseOncology #CancerCare

RSVP for the CSO at ESMO event

Attend the Common Sense Oncology Symposium taking place at ESMO 2026 for an update on the movement and regional developments across the globe. Network with likeminded individuals and enjoy light...

docs.google.com
Common Sense Oncology
@csoncolOct 15
🚨 CSO at ESMO 2026 is 9 days away! This is your reminder to attend and hear updates on the movement and regional developments across the globe. Network with likeminded individuals and enjoy light refreshments. Speakers will give short talks about CSO-aligned activities in their respective countries. There will be time for attendees to ask questions and talk about what’s happening in their own systems. Where: ESMO venue, IFEMA, Madrid, Spain - Room A6.1 When: Friday, October 23, 2026 - 18:00 - 19:30 Speakers: Dr. Winette van der Graaf, Dr. Dario Trapani, Dr. Chris Booth, Dr. Rodrigo Lastra del Prado, Dr. Francesco Perrone, Dr. Jolien Tol, Antonella Cardone Planning to attend? RSVP here to let us know! (RSVP is NOT mandatory to attend.) forms.gle/fxfDXnN9xAj3QseR9 #CancerCare #CommonSenseOncology
1
1
1
6
504
Indeed. And the patients (and physicians) should know from reading a clinical trial report what to expect- onset, severity, duration, impact on QOL, possibility of serious and fatal adverse events, all. academic.oup.com/jnci/advanc…
Mina S. Sedrak
@minasedrakmdOct 16
"The best medicine is the medicine you can take." Heard at the @BCRFcure Symposium, and it's the heart of what we are doing in our work as researchers. If patients can't tolerate a treatment, they can't benefit from it. #bcsm @oncology_bg
1
7
1
12
1,176
Just published in @JNCI_Now led by @lateuwen and in collaboration with @ChernyNathan. We provide specific recommendations for improved adverse event reporting in cancer clinical trials. For a true shared decision making, these items are necessary, not “good to have”. academic.oup.com/jnci/advanc…
1
9
1
27
1,850
Dr Deme Karikios retweeted
Common Sense Oncology
@csoncolOct 15
🚨 CSO at ESMO 2026 is 9 days away! This is your reminder to attend and hear updates on the movement and regional developments across the globe. Network with likeminded individuals and enjoy light refreshments. Speakers will give short talks about CSO-aligned activities in their respective countries. There will be time for attendees to ask questions and talk about what’s happening in their own systems. Where: ESMO venue, IFEMA, Madrid, Spain - Room A6.1 When: Friday, October 23, 2026 - 18:00 - 19:30 Speakers: Dr. Winette van der Graaf, Dr. Dario Trapani, Dr. Chris Booth, Dr. Rodrigo Lastra del Prado, Dr. Francesco Perrone, Dr. Jolien Tol, Antonella Cardone Planning to attend? RSVP here to let us know! (RSVP is NOT mandatory to attend.) forms.gle/fxfDXnN9xAj3QseR9 #CancerCare #CommonSenseOncology
1
4
1
7
645
Dr Deme Karikios retweeted
Common Sense Oncology
@csoncolSep 17
Attend the Common Sense Oncology Symposium taking place at ESMO 2026 for an update on the movement and regional developments across the globe. Network with likeminded individuals and enjoy light refreshments. Speakers will give short talks about CSO-aligned activities in their respective countries. There will be time for attendees to ask questions and talk about what’s happening in their own systems. Where: ESMO venue, IFEMA, Madrid, Spain - Room A6.1 When: Friday, October 23, 2026 - 18:00 - 19:30 Speakers: Dr. Winnette van der Graaf, Dr. Dario Trapani, Dr. Chris Booth, Dr. Rodrigo Lastra, Dr. Francesco Perrone, Dr. Jolien Tol, Antonella Cardone Planning to attend? RSVP below to let us know! forms.gle/ckfCobUbPg15HMRB6 @myESMO #CommonSenseOncology #CancerCare
11
17
788
Once in a while I get to read an article so good that I hope the rest of the world also reads it. Go home, drink the good wine, and read this. Superb editorial from @Prof_IanD : ascopubs.org/doi/10.1200/OP-…

How Do I Treat the Very Elderly With Advanced Bladder Cancer as We Have so Many New Agents? | JCO...

ascopubs.org
5
27
1
86
14,376
Dr Deme Karikios retweeted
Jia (Jenny) Liu MD PhD
@JiaJennyLiuSep 20
#ACORD26 off to a flying start! Thanks @myESMO @AACR @ASCO @CancerAustralia and many other sponsors for support! @oncodocsydney @MOGA_ORG @ACORDISM
1
6
1
17
2,703
Dr Deme Karikios retweeted
Hidehito HORINOUCHI
@HHorinouchiSep 13
🆙#WCLC26 #LCSM Plenary Session 🔥TAISHAN-302: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study 🎙️Dr. Li Zhang 🎯PFS HR 0.29 (95% CI 0.23-0.37) 🎯OS HR 0.46 (95% CI 0.35-0.62) 🔢PL02.03 ☑️NCT06612151 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
Hidehito HORINOUCHI
@HHorinouchiAug 20
🆙#WCLC26 #LCSM Plenary Session 🔥TAISHAN-302: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study 🎙️Dr. Li Zhang 🔢PL02.03 ☑️NCT06612151 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
4
1
11
4,644
Dr Deme Karikios retweeted
Prof Tom John@TommyJohn00Sep 12
Practice changing #SWOG S18 MAVERICK trial by C Rusthoven. I think this should be seen as then end of using PCI in SCLC. Endpoints changed bc slow recruitment. Although more CNS mets pfs was the same. Less toxicity, which increases over time. Not a surprise, but well conducted.
2
15
36
1,690
Dr Deme Karikios retweeted
Annie Wong 黃毅敏@anmwongNZSep 12
Replying to @IASLC
@IASLC plenary Phase III MAVERICK study: MRI improved cognitive failure free survival compared to prophylactic PCI in SCLC. 🙌 “De-escalation” requires reshaping models of care ➡️ensuring access to MRI will be essential 🧐Would like to see more functional/QoL data #WCLC26
6
13
512
Why attend the YOGA SHAPING YOUR ONCOLOGY CAREER PATH Workshop? 💡Explore career pathways 👂Hear real-world insights 🤝Connect with peers 🔎Get practical career advice 📅 7 & 8 November 2026 📍 Sofitel Gold Coast Broadbeach QLD 👉 Register now! moga.org.au/2026-oncology-ca… #YOGA
3
4
271
🌟 Meet our new MOGA QLD State Trainee Representative, Dr Hannah Keal! Hannah is a 2nd-year Advanced Trainee based on the Gold Coast, with experience working across regional and metropolitan Queensland. Welcome to the MOGA team, Hannah! 👏 #MOGA #MedicalOncology #TraineeLife
1
2
150
Interested in developing your expertise in thoracic oncology? TOGA’s 2026 Lung Cancer Preceptorship provides early-career clinicians with the opportunity to learn from experienced clinicians, engage in practical case-based discussions and build connections with others working
1
1
2
116
🩺 YOGA | Shaping Your Oncology Career Path 📅 7–8 Nov 2026 📍 Sofitel Gold Coast Broadbeach, QLD A practical 1.5 day workshop for early-career oncologists transitioning to consultant life. ✈️ Travel support available Register👉 moga.org.au/2026-oncology-ca…
1
2
119
Dr Deme Karikios retweeted
Common Sense Oncology
@csoncolAug 25
Are you an early-career oncologist looking to gain experience in health services research, cancer policy, and hands-on experience in the clinic? Common Sense Oncology invites you to apply for a one-year Cancer Health Services Research Fellowship in Kingston, Canada! Applications are due by September 1. Learn more and apply now: tinyurl.com/y8pdw3yv #CommonSenseOncology #CancerCare
3
3
504
Dr Deme Karikios retweeted
Jia (Jenny) Liu MD PhD
@JiaJennyLiuAug 21
#ACORD26 is less than a month away! 72 attendees + 36 faculty from across the Asia-Pacific and beyond, coming together to learn how to turn great ideas into executable, fundable oncology research. Beyond writing excellent protocols, we will be covering scientific pitching, industry-academia partnerships to building multidisciplinary teams This is the part of research we don’t teach enough. @ACORDISM @MartinStockler @oncodocsydney
1
5
2
18
2,584
Take your lung cancer knowledge to the next level. TOGA’s 2026 Lung Cancer Preceptorship brings together early-career clinicians for two days of expert-led education, interactive case discussions and multidisciplinary learning. 📅 Dates: November 20-21 📍 Location: Sydney
1
1
3
170
Learn. Discuss. Challenge. Grow. TOGA's 2026 Lung Cancer Preceptorship offers an immersive learning experience for early-career clinicians, combining expert-led education, case discussions and multidisciplinary collaboration. 📅 Dates: November 20-21 📍 Location: Sydney
1
1
1
109
Ready to challenge yourself and expand your expertise? The TOGA 2026 Lung Cancer Preceptorship is designed to support the next generation of thoracic oncology clinicians through expert-led education, interactive discussions and practical learning. 📅 Dates: November 20-21
1
1
2
113
Dr Deme Karikios retweeted
Jia (Jenny) Liu MD PhD
@JiaJennyLiuAug 5
Replying to @SuyogCancer @oncology_bg @Dr_R_Kurzrock @dr_yakupergun
I agree with your synthesis and understand both sides of the debate between OS and ORR. With increasing drug herding, OS will be contaminated as patients on control arms being able to access “me too drugs” via early phase trials. But what is missing entirely in this is HOW patients are living. QoL and thriving with cancer (retaining function, wellbeing, identity) is something we measure very poorly on trials but probably one of the most important endpoints from a patient POV. Hard to measure as it is a multifactorial endpoint that includes financial and time toxicity.
4
2
13
934
Load more